Capital Fund Management (CFM)’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-285,867
| Closed | -$10.5M | – | 2138 |
|
|
2024
Q4 | $9.67M | Buy |
285,867
+225,801
| +376% | +$8.13M | 0.02% | 761 |
|
|
2024
Q3 | $2.46M | Buy |
+60,066
| New | +$2.46M | 0.01% | 1336 |
|
|
2024
Q2 | – | Sell |
-68,842
| Closed | -$2.9M | – | 1989 |
|
|
2024
Q1 | $2.95M | Sell |
68,842
-316,884
| -82% | -$13.1M | 0.01% | 1264 |
|
|
2023
Q4 | $14.3M | Buy |
385,726
+193,555
| +101% | +$6.95M | 0.04% | 600 |
|
|
2023
Q3 | $6.97M | Buy |
192,171
+88,267
| +85% | +$3.13M | 0.02% | 775 |
|
|
2023
Q2 | $3.7M | Sell |
103,904
-59,875
| -37% | -$2.15M | 0.02% | 963 |
|
|
2023
Q1 | $5.83M | Sell |
163,779
-499,322
| -75% | -$17.5M | 0.03% | 683 |
|
|
2022
Q4 | $23.3M | Buy |
663,101
+28,146
| +4% | +$938K | 0.16% | 171 |
|
|
2022
Q3 | $18.7M | Buy |
+634,955
| New | +$24.1M | 0.15% | 180 |
|
|
2020
Q3 | – | Sell |
-31,218
| Closed | -$1.59M | – | 1279 |
|
|
2020
Q2 | $1.59M | Sell |
31,218
-88,635
| -74% | -$4.55M | 0.03% | 568 |
|
|
2020
Q1 | $5.68M | Buy |
119,853
+39,893
| +50% | +$2.13M | 0.09% | 285 |
|
|
2019
Q4 | $4.7M | Buy |
79,960
+17,168
| +27% | +$955K | 0.04% | 557 |
|
|
2019
Q3 | $3.35M | Buy |
+62,792
| New | +$3.23M | 0.03% | 615 |
|
|
2019
Q2 | – | Sell |
-83,418
| Closed | -$4.36M | – | 1737 |
|
|
2019
Q1 | $4.36M | Buy |
83,418
+27,768
| +50% | +$1.39M | 0.04% | 540 |
|
|
2018
Q4 | $2.66M | Buy |
+55,650
| New | +$2.74M | 0.02% | 736 |
|
|
2017
Q2 | – | Sell |
-11,163
| Closed | -$588K | – | 1557 |
|
|
2017
Q1 | $588K | Buy |
+11,163
| New | +$566K | ﹤0.01% | 1083 |
|
|
2016
Q4 | – | Sell |
-13,074
| Closed | -$705K | – | 1735 |
|
|
2016
Q3 | $705K | Sell |
13,074
-43,309
| -77% | -$2.37M | 0.01% | 1079 |
|
|
2016
Q2 | $3.06M | Sell |
56,383
-192,445
| -77% | -$10.1M | 0.03% | 587 |
|
|
2016
Q1 | $12.6M | Buy |
248,828
+230,480
| +1,256% | +$11.5M | 0.12% | 209 |
|
|
2015
Q4 | $925K | Buy |
+18,348
| New | +$935K | 0.01% | 902 |
|
|
2015
Q1 | – | Sell |
-185,355
| Closed | -$10.6M | – | 1559 |
|
|
2014
Q4 | $9.9M | Buy |
+185,355
| New | +$10.4M | 0.12% | 240 |
|
|
2014
Q3 | – | Sell |
-245,985
| Closed | -$15.1M | – | 1617 |
|
|
2014
Q2 | $16.4M | Buy |
245,985
+56,151
| +30% | +$3.8M | 0.17% | 137 |
|
|
2014
Q1 | $12.7M | Buy |
+189,834
| New | +$12.8M | 0.16% | 154 |
|
Other funds holding GSK
JEST
Capital Fund Management (CFM)'s GSK Position: Q1 2025 in Review
Capital Fund Management (CFM) sold out of GSK (GSK) in Q1 2025, closing a stake of 285,867 shares — an estimated $10.5M sold.
Capital Fund Management (CFM) first reported a position in GSK in Q1 2014 and held it in 23 quarters. The position peaked at $23.3M in Q4 2022. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.
- Capital Fund Management (CFM) reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
- Capital Fund Management (CFM) sold 285,867 GSK shares in Q1 2025, an estimated $10.5M.
- Capital Fund Management (CFM) first reported a position in GSK in Q1 2014 and held it in 23 quarters.
- Capital Fund Management (CFM)'s GSK position peaked at $23.3M in Q4 2022.
- 857 funds tracked by Wall St. Rank held GSK as of Q1 2025.
Based on Capital Fund Management (CFM)'s 13F filing for Q1 2025, filed 14 May 2025.